Getinge


09/06/21 -"Our target price hike is largely attributable to an increase in our peer-based valuations, as we have factored in a premium of 20% vs none earlier. We believe, given the recovery from the quality ..."

Pages
60
Language
English
Published on
09/06/21
You may also be interested by these reports :
04/11/25
Philips’ Q3 profitability exceeded expectations. Comparable top-line growth was driven by robust performance in Personal Health and Connected Care. ...

04/11/25
FMC posted strong Q3 results, driven by cost savings and growth across segments, thereby helping to reiterate the 2025 outlook. Despite the results ...

31/10/25
Drägerwerk’s delivered solid Q3 2025 numbers. Revenue rose 10.1% to €833 million, driving a substantial 370bps EBIT margin expansion to 6.8%. This, ...

30/10/25
Amplifon’s Q3 results did not meet the company-compiled consensus. Sales growth was supported by strong performance in the Americas and a recovery in ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO